Back to Search
Start Over
1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial.
- Source :
-
Annals of Oncology . 2023 Supplement 2, Vol. 34, pS975-S976. 2p. - Publication Year :
- 2023
- Subjects :
- *CASTRATION-resistant prostate cancer
*OLAPARIB
*PLACEBOS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 34
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 173099406
- Full Text :
- https://doi.org/10.1016/j.annonc.2023.09.2753